Bayer Schering Pharmaceuticals announced a $1.9 million pledge to develop hemophilia treatment centers (HTCs) throughout China. The funding will support a number of the project’s key components, including medical training, equipment and supplies, patient programs, nursing support and educational materials.
A partnership between Bayer Schering Pharmaceuticals of Germany and the Chinese Society of Hematology, The Bayer China Hemophilia Treatment Center Development Project will focus on enhancing the lives of hemophilia patients throughout China with an emphasis on diagnosis and comprehensive care. Approximately one quarter of the world’s hemophilia population lives in China, with estimates ranging from 70,000 to 100,000 individuals. However, China has only six HTCs. These existing centers, which are part of the HTC Collaborative Network of China, will be further developed and strengthened as part of the Bayer-funded program.
“The Bayer China Hemophilia Treatment Center Development Project is a massive investment in the health and well-being of our society in an area of critical unmet need,” said.Professor Ruan Changgeng, President, Chinese Society of Hematology. “Through Bayer's generous support and our own commitment to improving access to care, patients and their families will receive the best possible support through a team of dedicated professionals.”
Source: PR Newswire, November 13, 2008